Lemtrada

(alemtuzumab)
1.2 ML alemtuzumab 10 MG/ML Injection [Lemtrada]

Dosage & administration

Most viewed Lemtrada resources

Enroll in patients savings program (Phone Number)

drug label

Lemtrada prescribing information

Have more Lemtrada questions?

Submit MSL Request
Learn More

Need to report a Lemtrada issue?

ONLINE FORM
Report adverse event
Learn More

prior authorization

Lemtrada Prior authorization resources

NOT PROVIDED BY BRAND
Complete Letter of Medical Necessity

NOT PROVIDED BY BRAND
Coverage Authorization Request

NOT PROVIDED BY BRAND
Coverage Authorization Appeals
Learn More

Benefits investigation

Lemtrada Service Form
Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRAND
Reimbursement help (FRM) resources
Learn More

financial assistance

Lemtrada Financial assistance options

Co-pay savings program

commercial only
Enroll in patients savings program (Phone Number)
Lemtrada Service Form
Learn More

Bridge program

commercial only
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Learn More

patient education

Lemtrada Patient education

Getting started on Lemtrada

NOT PROVIDED BY BRAND
Intructions for Use - Multiple Sclerosis

Patient toolkit

Patient Stories
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Lemtrada
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Lemtrada FAQs

What is the risk of using LEMTRADA in pregnant women?There are no adequate data on the developmental risk associated with the use of LEMTRADA in pregnant women. LEMTRADA was embryolethal in pregnant huCD52 transgenic mice when administered during organogenesis. Auto-antibodies may develop after administration of LEMTRADA. Placental transfer of anti-thyroid antibodies resulting in neonatal Graves’ disease has been reported.
What is the background risk of birth defects and miscarriage with LEMTRADA?The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Is there a pregnancy surveillance program for LEMTRADA?Yes, there is a pregnancy surveillance program for LEMTRADA. If LEMTRADA exposure occurs during pregnancy, healthcare providers and patients are encouraged to report pregnancies by calling 1-800-745-4447, option 2.
What are the clinical considerations for pregnant women using LEMTRADA?LEMTRADA induces persistent thyroid disorders. Untreated hypothyroidism in pregnant women increases the risk for miscarriage and may have effects on the fetus including mental retardation and dwarfism. In mothers with Graves’ disease, maternal thyroid stimulating hormone receptor antibodies can be transferred to a developing fetus and can cause neonatal Graves’ disease.
Is alemtuzumab present in human milk?There are no data on the presence of alemtuzumab in human milk, but alemtuzumab was detected in the milk of lactating huCD52 transgenic mice administered LEMTRADA.
What are the developmental and health benefits of breastfeeding when using LEMTRADA?The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for LEMTRADA and any potential adverse effects on the breastfed child from LEMTRADA or from the underlying maternal conditions.
Is LEMTRADA safe and effective for pediatric patients?No, safety and effectiveness of LEMTRADA have not been established in pediatric patients under the age of 17. Due to the risks of autoimmunity, infusion reactions, stroke, and increased risk of malignancies (thyroid, melanoma, lymphoproliferative disorders, and lymphoma), the use of LEMTRADA is not recommended in pediatric patients. Please see Warnings and Precautions (5.1, 5.2, 5.3, 5.4) for more information.
Is LEMTRADA safe and effective for geriatric patients?There is not enough clinical data to determine if LEMTRADA is safe and effective for patients aged 65 and over. Further studies are needed to evaluate whether geriatric patients respond differently than younger patients.
FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:
Please note:
  • Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
  • Samples are provided at the discretion of the brand.
  • We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.